Latest Institutional Placement News

EQ Resources has successfully raised $22.5 million through an institutional placement, aiming to accelerate production and strengthen its financial position at the Mt Carbine tungsten project.

Dateline Resources has secured $25 million in an institutional placement to accelerate exploration and development at its Colosseum Gold-REE Project in California, backed by strong U.S. government support and promising new targets.

Catalyst Metals Limited reported record FY2025 financial results driven by stable operations at the Plutonic Gold Belt and a buoyant gold price environment. The company plans to double annual gold production to 200koz through development of new mines and expanded exploration.

Cyprium Metals Limited has launched an A$80 million capital raise to fast-track the restart of its Nifty Copper Complex, aiming to unlock significant value from its brownfield assets. The funds will support refurbishment, feasibility studies, and strengthen the company’s balance sheet.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

IMEXHS Limited reported a $3 million net loss for the half-year ending June 2025, driven by a significant goodwill impairment, while annualised recurring revenue rose 11%. The company completed a $2.6 million capital raise to support growth amid ongoing cost optimisation and automation efforts.

Lynas Rare Earths has successfully completed a A$750 million institutional placement, strengthening its balance sheet to fund ambitious growth plans under its Towards 2030 strategy.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Core Lithium has successfully raised $50 million through a two-tranche institutional placement, complemented by a $10 million Share Purchase Plan, to accelerate its Finniss Lithium Project towards a Final Investment Decision.

Cyprium Metals unveils a rapid restart plan for its Nifty Copper Complex, backed by a substantial A$80 million capital raise to fund early cash flow and long-term growth. The project boasts a pre-tax NPV of A$1.1 billion, positioning Cyprium as a compelling copper play on the ASX.